These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Omalizumab (Xolair). Product description].
    Author: Laursen LC.
    Journal: Ugeskr Laeger; 2007 Mar 12; 169(11):993-5. PubMed ID: 17371630.
    Abstract:
    Xolair, Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin E (IgE). Currently, omalizumab has been approved for the treatment of persistent allergic asthma in patients who are poorly controlled with inhaled corticosteroids. However, other allergic disorders may be amenable to treatment with omalizumab because of its ability to inhibit effector functions of IgE. Treatment with omalizumab should be administered by specialists with training in diagnosis and treatment of allergic asthma. The treatment should be withheld if no positive treatment effects are observed after 4 months.
    [Abstract] [Full Text] [Related] [New Search]